氯替泼诺混悬滴眼液(Lotemax)的用药注意事项

Loteprednol suspension eye drops (Lotemax) was developed by Bausch & Lomb of the United States and was first approved for marketing in the United States in 1998.

Precautions for Loteprednol Suspension Eye Drops (Lotemax)

1. Long-term use of corticosteroids may lead to glaucoma, optic nerve damage, vision and visual field defects, and posterior subcapsular cataract formation. People with glaucoma should use steroids with caution.

2. Long-term use of corticosteroids may suppress the host's immune response, thereby increasing the risk of secondary eye infections. Perforation has been known to occur with the use of topical steroids in diseases that cause thinning of the cornea or sclera. In acute suppurative eye disease, steroids may mask infection or worsen existing infection.

3. The use of ocular steroids may prolong the course of the disease and aggravate the severity of various eye viral infections (including herpes simplex). Use of corticosteroids with extreme caution in patients with a history of herpes simplex.

4. The use of steroids after cataract surgery may delay healing and increase the incidence of follicle formation.

5. For ophthalmic use only. Initial prescriptions and refills older than 14 days must be made by a physician after examining the patient with a magnifying device (such as a slit lamp biomicroscope) and, if appropriate, fluorescein staining.

6. If signs and symptoms do not improve after two days, the patient should be re-evaluated.

7. If this product is used for 10 days or more, intraocular pressure should be monitored, although this may be difficult in children and uncooperative patients.

8. Long-term use of topical steroids is particularly prone to corneal fungal infection. In any persistent corneal ulcer, fungal attack must be considered if steroids have been or are being used. Fungal culture should be performed when appropriate.

The pictures come from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Indications of Loteprednol Suspension Eye Drops (Lotemax)

Loteprednol is suitable for the treatment of steroid-sensitive inflammation of the eyelid conjunctiva, bulbar conjunctiva, cornea and anterior segment of the globe, such as allergies Conjunctivitis, rosacea, superficial punctate keratitis, herpetic keratitis, iritis, cyclitis, and certain infectious conjunctivitis while accepting the inherent risks associated with steroid use to achieve modest resolution of edema and inflammation.

Special Population Use of Loteprednol Suspension Eye Drops (Lotemax)

1. Breastfeeding women

It is unclear whether topical ophthalmic administration of corticosteroids will result in sufficient systemic absorption to produce detectable amounts in human milk. Systemic steroids occur in human milk and may inhibit growth, interfere with endogenous corticosteroid production, or cause other adverse effects. Caution should be used when using loteprednol in nursing mothers.

2. Pediatric use

The safety and effectiveness in pediatric patients have not been established.

Adverse Reactions of Loteprednol Suspension Eye Drops (Lotemax)

Reactions associated with ophthalmic steroids include increased intraocular pressure (possibly related to optic nerve damage), visual acuity and visual field defects, posterior subcapsular cataract formation, secondary ocular infections caused by pathogens (including herpes simplex), and globe perforation where the cornea or sclera is thinned.

In clinical studies, ocular adverse reactions with an incidence rate between 5% and 15% in patients treated with loteprednol carbonate ophthalmic suspension (0.2%-0.5%) include: abnormal/blurred vision, burning sensation during instillation, bulbar conjunctival edema, discharge, dry eyes, epiphora, foreign body sensation, itching, congestion and photophobia.

Other ocular adverse reactions with an incidence of less than 5% include: conjunctivitis, corneal abnormalities, eyelid erythema, keratoconjunctivitis, ocular irritation/pain/discomfort, papillary conjunctivitis, and uveitis. Some of these events were similar to the underlying eye disease studied.

The incidence of non-ocular adverse reactions was less than 15%, including headache, rhinitis and pharyngitis.